Given the complexity and distinct pathophysiology of immune-mediated neurological diseases, the present study specifically focused on NMOSD seropositive for AQP4-IgG and NMOSD seronegative for both AQP4-IgG and MOG-IgG, in agreement with the 2015 IPND diagnostic criteria.1It is noteworthy to emphasize that the current consensus does not address, and its recommendations are not intended for, other immune-mediated conditions such as MOGAD, once this is now recognized as distinct entity. The gene discussed is AQP4; the disease is nervous system disorder.